Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of AL01211 in treatment-naive men with classic Fabry disease
CTR20231170Phase 2Active
- Sponsor
- Aisilinco
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AL01211 in Fabry disease (FD), sponsored by Aisilinco. Started Oct 2023; status: active.
02
Drugs
AL01211
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on CTR20231170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231170.